There are, however, no adequate and well-controlled studies in pregnant women. No emetic episodes occurred in 314 (79%) of the re-treatment courses, and only 1 to 2 emetic episodes occurred in 43 (11%) of the re-treatment courses.Three open-label, uncontrolled, foreign trials have been performed with 182 pediatric patients 4 to 18 years old with cancer who were given a variety of cisplatin or noncisplatin regimens. It is not known whether these gender-related differences were clinically important. Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron.In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.Gender differences were shown in the disposition of ondansetron given as a single dose. It is not known whether ondansetron is excreted in human milk. Typical duration of therapy is until ondansetron no longer works in relieving nausea and vomiting or nausea has resolved and ondansetron is no longer needed. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Ondansetron/Possible QT Prolonging Agents Interactions This information is generalized and not intended as specific medical advice. No dosage adjustment is recommended in the elderly.In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in normals. The dosage recommendation is the same as for the general populationThe recommended adult oral dosage is one 8 mg ondansetron tablet given twice a day. doctor or pharmacist) for more information.Ondansetron can affect your heart's rhythm. Hypotension (and faintness) occurred in a patient that took 48 mg of ondansetron tablets.

Total body irradiation consisted of 11 fractions (120 cGy per fraction) over 4 days for a total of 1,320 cGy. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. The active ingredient in ondansetron tablets is ondansetron hydrochloride (HCl) as the dihydrate, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HTOndansetron HCl dihydrate is a white to off-white powder that is soluble in water and normal saline.Each 4 mg ondansetron tablet, USP for oral administration contains ondansetron hydrochloride dihydrate equivalent to 4 mg of ondansetron. Pharmacokinetics in Normal Volunteers: Single 24 mg Ondansetron tablets DoseTable 5. Several medications have been shown to help with symptoms, including clonidine (a blood pressure medication), low doses of certain antidepressants (such as venlafaxine and Prozac), and gabapentin. Following infusion of 32 mg over only a 4-minute period, a vasovagal episode with transient second-degree heart block was observed.

Except for bronchospasm and anaphylaxis, the relationship to ondansetron tablets were unclear.The adverse events reported in patients receiving ondansetron tablets and concurrent radiotherapy were similar to those reported in patients receiving ondansetron tablets and concurrent chemotherapy. Slower clearance in women, a smaller apparent volume of distribution (adjusted for weight), and higher absolute bioavailability resulted in higher plasma ondansetron levels. Dosing. The active ingredient in ondansetron tablets is ondansetron hydrochloride (HCl) as the dihydrate, the racemic form of ondansetron and a selective blocking agent of the serotonin 5-HT 3 receptor type. Choose from 500 different sets of medication list medications 3 name recognition flashcards on Quizlet. If you are a consumer or patient please visit The results of this study are summarized in Table 3:In 1 double-blind US study in 336 patients, ondansetron tablets  8 mg administered twice a day were as effective as ondansetron tablets 8 mg administered 3 times a day in preventing nausea and vomiting induced by cyclophosphamide-based chemotherapy containing either methotrexate or doxorubicin. Interactions with general or local anesthetics have not been studied.Ondansetron is well absorbed from the gastrointestinal tract and undergoes some first-pass metabolism. Medical warning: Moderate. Torsades de pointes (TdP) is an ECG manifestation characterized by a form of ventricular tachycardia with a spiral appearance and complexes that first look positive and then negative. The events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to ondansetron tablets.Rarely and predominantly with intravenous ondansetron, transient ECG changes including QT interval prolongation have been reported.Flushing. Frequency of Adverse Events From Controlled Studies With Ondansetron tablets (Postoperative Nausea and Vomiting)For single high-dose fraction radiotherapy to the abdomenStore at 20° - 25°C (68° - 77°F) [See USP Controlled Room Temperature]. Your doctor may want to perform an electrocardiogram (ECG) on you to check your heart rate and rhythm.